

# Nicola Nicolai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5132962/publications.pdf>

Version: 2024-02-01

122  
papers

5,931  
citations

101543

36  
h-index

76900

74  
g-index

128  
all docs

128  
docs citations

128  
times ranked

5023  
citing authors

#	ARTICLE	IF	CITATIONS
1	External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection. World Journal of Urology, 2023, 41, 619-625.	2.2	8
2	New Landmarks Towards Reducing the Treatment Burden for Patients with a Postchemotherapy Residual Retroperitoneal Mass from Nonseminomatous Germ-cell Testicular Tumors. European Urology Oncology, 2022, , .	5.4	0
3	Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World Journal of Urology, 2022, 40, 1505-1512.	2.2	12
4	How to implement the requirements of a quality assurance system for prostate cancer. World Journal of Urology, 2021, 39, 41-47.	2.2	1
5	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	10.7	48
6	Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?. Frontiers in Psychology, 2020, 11, 576459.	2.1	7
7	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	1.9	148
8	Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. Critical Reviews in Oncology/Hematology, 2019, 137, 154-164.	4.4	5
9	Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes. European Urology Focus, 2019, 5, 737-741.	3.1	25
10	Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. European Journal of Surgical Oncology, 2019, 45, 60-66.	1.0	4
11	Non-“risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary. European Urology, 2018, 73, 899-907.	1.9	51
12	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	6.4	12
13	Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. European Urology, 2018, 73, 394-405.	1.9	78
14	Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. Clinical Genitourinary Cancer, 2018, 16, e403-e410.	1.9	11
15	First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU International, 2018, 121, 348-356.	2.5	70
16	Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 8.e1-8.e8.	1.6	8
17	Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. Journal of Urology, 2018, 199, 741-747.	0.4	21
18	ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, 1658-1686.	1.2	228

#	ARTICLE	IF	CITATIONS
19	Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience. <i>Tumori</i> , 2018, 104, 388-393.	1.1	2
20	Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance. <i>Tumori</i> , 2018, 104, 172-178.	1.1	5
21	Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 60-65.	1.3	4
22	Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e483-e487.	1.9	7
23	Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. <i>Annals of Oncology</i> , 2017, 28, 1346-1351.	1.2	34
24	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 548-555.e3.	1.9	37
25	Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 605.e17-605.e23.	1.6	39
26	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 213-220.e5.	1.9	27
27	A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 306-312.e3.	1.9	25
28	Personalise Medicine, Do Not Medicalise Persons. <i>European Urology</i> , 2017, 71, 128-129.	1.9	0
29	Changes in Mortality and Incidence of Prostate Cancer by Risk Class in Different Periods in Italy: The Possible Effects of PSA Spread. <i>Tumori</i> , 2017, 103, 292-298.	1.1	1
30	Andrological complications following retroperitoneal lymph node dissection for testicular cancer. <i>Minerva Urology and Nephrology</i> , 2017, 69, 209-219.	2.5	6
31	Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?. <i>Tumori</i> , 2017, 103, 464-474.	1.1	20
32	Interim 18F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 249-254.	1.9	12
33	Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 261-264.e4.	1.9	22
34	Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 518-523.	1.9	28
35	Frozen Section in Testicular Pathology. , 2016, , 203-212.		2
36	Prognostic and Predictive Factors in Pathology of the Testis. , 2016, , 159-164.		0

#	ARTICLE	IF	CITATIONS
37	Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. <i>European Journal of Cancer</i> , 2016, 67, 91-98.	2.8	17
38	Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. <i>Journal of Endourology</i> , 2016, 30, 1112-1119.	2.1	20
39	The role of surgery in metastatic squamous cell carcinoma of the penis. <i>Current Opinion in Urology</i> , 2016, 26, 596-601.	1.8	4
40	Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. <i>Journal of Urology</i> , 2016, 196, 95-100.	0.4	70
41	Estimates of prostate cancer burden in Italy. <i>Cancer Epidemiology</i> , 2016, 40, 166-172.	1.9	10
42	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016, 34, 236-242.	2.6	21
43	A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 323-330.	1.9	59
44	Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 231-236.	1.9	38
45	The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 1-4.	1.9	6
46	Extent of pelvic lymph node dissection in penile cancer may impact survival. <i>World Journal of Urology</i> , 2016, 34, 353-359.	2.2	32
47	Survival of male genital cancers (prostate, testis and penis) in Europe 1999â€“2007: Results from the EUROCARE-5 study. <i>European Journal of Cancer</i> , 2015, 51, 2206-2216.	2.8	82
48	Quality of Life and Pain Control following Laparoscopic Retroperitoneal Lymph Node Dissection in Early-stage Nonseminoma. <i>Tumori</i> , 2015, 101, 650-656.	1.1	6
49	Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases. <i>BJU International</i> , 2015, 116, 727-733.	2.5	23
50	Establishing Criteria for Bilateral Pelvic Lymph Node Dissection in the Management of Penile Cancer: Lessons Learned from an International Multicenter Collaboration. <i>Journal of Urology</i> , 2015, 194, 696-702.	0.4	37
51	Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 80-86.e1.	1.9	17
52	Clinical Outcome in Testicular Sex Cord Stromal Tumors: Testis Sparing vs Radical Orchiectomy and Management of Advanced Disease. <i>Urology</i> , 2015, 85, 402-406.	1.0	47
53	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 332.e19-332.e24.	1.6	12
54	Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 385-391.e1.	1.9	4

#	ARTICLE	IF	CITATIONS
55	Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. <i>Annals of Oncology</i> , 2015, 26, 657-668.	1.2	71
56	Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 171-177.e1.	1.9	9
57	Guidelines on Testicular Cancer: 2015 Update. <i>European Urology</i> , 2015, 68, 1054-1068.	1.9	538
58	Adjuvant chemotherapy is associated with improved overall survival in pelvic node-â€“positive penile cancer after lymph node dissection: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 496.e17-496.e23.	1.6	76
59	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. <i>Annals of Oncology</i> , 2015, 26, 167-172.	1.2	17
60	A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 87-93.e1.	1.9	27
61	Is There Still an Indication for Primary RPLND in Clinical Stage I Non-seminoma?. , 2015, , 29-54.		0
62	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. <i>British Journal of Cancer</i> , 2014, 110, 26-33.	6.4	16
63	Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 203-209.e1.	1.9	15
64	Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 196-202.e1.	1.9	3
65	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor Î² (TGFÎ²) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. <i>Investigational New Drugs</i> , 2014, 32, 555-560.	2.6	50
66	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	1.9	195
67	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 433-439.	1.9	24
68	Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 63-69.e1.	1.9	27
69	The Relationship between Characteristics of Inguinal Lymph Nodes and Pelvic Lymph Node Involvement in Penile Squamous Cell Carcinoma: A Single Institution Experience. <i>Journal of Urology</i> , 2014, 191, 977-982.	0.4	75
70	Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 376-376.	1.6	5
71	Survival analyses of adjuvant or neoadjuvant combination of a taxane plus cisplatin and 5-fluorouracil (T-PF) in patients with bulky nodal metastases from squamous cell carcinoma of the penis (PSCC): Results of a single high-volume center.. <i>Journal of Clinical Oncology</i> , 2014, 32, 377-377.	1.6	11
72	Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status. <i>PLoS ONE</i> , 2014, 9, e86659.	2.5	10

#	ARTICLE	IF	CITATIONS
73	Corrigendum to "Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe" [Eur. J. Cancer 48 (2) (2012) 159-169]. European Journal of Cancer, 2013, 49, 766.	2.8	2
74	Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes. Annals of Oncology, 2013, 24, 2887-2892.	1.2	14
75	Has Dynamic Sentinel Node Biopsy Achieved Its Top Performance in Penile Cancer? What Clinicians Still Need to Manage Lymph Nodes in Early Stage Penile Cancer. European Urology, 2013, 63, 664-666.	1.9	7
76	Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment. Journal of Urology, 2013, 190, 1919-1924.	0.4	36
77	709 POSITIVE NODE RATIO AND TOTAL NUMBER OF POSITIVE NODES MAY PREDICT RECURRENCE IN EARLY STAGE NON-SEMINOMATOUS GERM-CELL TUMOURS UNDERGOING PRIMARY RETROPERITONEAL LYMPH-NODE DISSECTION. Journal of Urology, 2013, 189, .	0.4	1
78	Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance. European Urology, 2013, 64, 30-36.	1.9	81
79	Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature. Tumori, 2013, 99, e203-7.	1.1	1
80	Experience with sorafenib in the treatment of advanced renal cell carcinoma. Therapeutic Advances in Urology, 2012, 4, 303-313.	2.0	17
81	Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. European Journal of Cancer, 2012, 48, 159-169.	2.8	37
82	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncology, The, 2012, 13, 810-816.	10.7	130
83	CT-guided percutaneous cryoablation of renal masses in selected patients. Radiologia Medica, 2012, 117, 593-605.	7.7	7
84	The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU International, 2012, 110, 998-1003.	2.5	47
85	Concordance and Prediction Ability of Original and Reviewed Vascular Invasion and Other Prognostic Parameters of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors After Retroperitoneal Lymph Node Dissection. Journal of Urology, 2011, 186, 1298-1302.	0.4	21
86	Targeted prostate cancer screening in men with mutations in <i>BRCA1</i> and <i>BRCA2</i> detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU International, 2011, 107, 28-39.	2.5	83
87	Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal. BJU International, 2011, 107, 1088-1094.	2.5	54
88	Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU International, 2011, 108, 223-227.	2.5	10
89	Reply to Ilker Akyol, Hasan Soydan, and Ferhat Ates Letter to the Editor re: Nicola Nicolai, Rosalba Miceli, Andrea Necchi, et al. Retroperitoneal Lymph Node Dissection With No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. Eur Urol 2010;58:912-8. European Urology, 2011, 59, e21-e22.	1.9	1
90	Teratoma With Somatic-Type Malignant Components in Germ Cell Tumors of the Testis: A Clinicopathologic Analysis of 40 Cases With Outcome Correlation. International Journal of Surgical Pathology, 2011, 19, 321-327.	0.8	66

#	ARTICLE	IF	CITATIONS
91	Proof of Activity of Anti-“Epidermal Growth Factor Receptor”-Targeted Therapy for Relapsed Squamous Cell Carcinoma of the Penis. <i>Journal of Clinical Oncology</i> , 2011, 29, e650-e652.	1.6	74
92	Re: Roisin M. Connolly, John A. McCaffrey. High-Dose Chemotherapy plus Stem Cell Transplantation in Advanced Germ Cell Cancer: A Review. <i>Eur Urol</i> 2009;56:57-64. <i>European Urology</i> , 2010, 57, e5-e6.	1.9	1
93	Retroperitoneal Lymph Node Dissection with No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. <i>European Urology</i> , 2010, 58, 912-918.	1.9	47
94	New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification. <i>BJU International</i> , 2010, 106, 168-179.	2.5	8
95	Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v140-v146.	1.2	76
96	Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v147-v154.	1.2	74
97	Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 4906-4911.	1.6	267
98	Thyroid as a Target of Metastases: A Case of Metastatic Seminoma in a Patient who Died of a Second Cancer. <i>Tumori</i> , 2009, 95, 91-93.	1.1	6
99	Taxanes in Combination with Cisplatin and Fluorouracil for Advanced Penile Cancer: Preliminary Results. <i>European Urology</i> , 2009, 55, 546-551.	1.9	127
100	Rebuttal from Authors re: Oliver W. Hakenberg. A New Neoadjuvant Chemotherapy Regimen for Penile Cancer with Nodal Metastases: A Step Forward. <i>Eur Urol</i> 2009;55:552-3. <i>European Urology</i> , 2009, 55, 554-555.	1.9	0
101	Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. <i>BJU International</i> , 2009, 104, 340-346.	2.5	34
102	Understanding the somatic-type malignant differentiation in male germ-cell cancer: A work in progress. Response to the article by Spiess et al., Malignant transformation of testicular teratoma: A chemoresistant phenotype. <i>Urol Oncol</i> 2008;26:595-9. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 218.	1.6	0
103	Penile cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 677-685.	1.6	20
104	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. <i>European Urology</i> , 2008, 53, 478-496.	1.9	488
105	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. <i>European Urology</i> , 2008, 53, 497-513.	1.9	243
106	Penoscopically Controlled CO2 Laser Excision for Conservative Treatment of In Situ and T1 Penile Carcinoma: Report on 224 Patients. <i>European Urology</i> , 2008, 54, 875-884.	1.9	115
107	Does oxaliplatin and paclitaxel combination show an activity of some extent in pretreated patients with germ-cell tumors?. <i>Annals of Oncology</i> , 2008, 19, 1509.	1.2	5
108	IGG* Practice Guidelines on Germ Cell Tumor in Adult Male Patients. <i>Tumori</i> , 2008, 94, 96-109.	1.1	12

#	ARTICLE	IF	CITATIONS
109	Short report. The AIDIT and IMPACT conference 2006: Outcomes and future directions. Hereditary Cancer in Clinical Practice, 2007, 5, 53.	1.5	1
110	Re: Peter Albers. Management of Stage I Testis Cancer. Eur Urol 2007;51:34-44. European Urology, 2007, 52, 295-296.	1.9	1
111	In regard to Kagan: "The multidisciplinary clinic" (Int J Radiat Oncol Biol Phys 2005;61:967-968). International Journal of Radiation Oncology Biology Physics, 2005, 63, 309-310.	0.8	13
112	European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Annals of Oncology, 2004, 15, 1377-1399.	1.2	441
113	A Simple Model for Predicting Nodal Metastasis in Patients With Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors Undergoing Retroperitoneal Lymph Node Dissection Only. Journal of Urology, 2004, 171, 172-176.	0.4	69
114	Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis in Childhood and Adolescence: An Analysis of 31 Cases. Journal of Pediatric Hematology/Oncology, 2002, 24, 454-458.	0.6	14
115	The Role of Adjuvant Treatment in Low-Stage Germ Cell Testicular Tumors. European Urology, 1995, 28, 267-272.	1.9	5
116	A Surveillance Study of Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: 10-Year Followup. Journal of Urology, 1995, 154, 1045-1049.	0.4	106
117	Evolution and controversies in the management of low-stage nonseminomatous germ-cell tumors of the testis. World Journal of Urology, 1994, 12, 113-9.	2.2	17
118	Surgery in Non-Seminomatous Germ Cell Tumours of the Testis. , 1994, , 311-317.		1
119	Dexamethasone plus Ondansetron versus Dexamethasone plus Alizapride in the Prevention of Emesis Induced by Cisplatin-Containing Chemotherapies for Urological Cancers. European Urology, 1993, 23, 450-456.	1.9	17
120	Comparison between Clinical and Pathological Staging in Low Stage Nonseminomatous Germ Cell Testicular Tumors. Journal of Urology, 1992, 148, 76-79.	0.4	37
121	Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results. Annals of Oncology, 1992, 3, 211-216.	1.2	24
122	Total embedding of spermatic cord and hilar soft tissue in orchiectomy for seminoma: does the extensive sampling improve pathologic risk factors?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 0, , .	2.8	0